We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.
Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.
Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.
A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.
Oxford Gene Technology announces the addition of accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications.
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
Harvard University's Wyss Institute of Biologically Inspired Engineering and its collaborating institutions, the Harvard John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Harvard's Department of Stem Cell and Regenerative Biology, announce the formation of a new NIH-funded Immuno-Engineering to Improve Immunotherapy Center.